Last reviewed · How we verify
montelukast and cetirizine
montelukast and cetirizine is a Leukotriene receptor antagonist and H1-receptor antagonist combination Small molecule drug developed by Medical University of Lodz. It is currently FDA-approved for Allergic rhinitis, Asthma (mild persistent), Allergic conditions with both leukotriene and histamine involvement.
This combination blocks leukotriene receptors (montelukast) and histamine H1 receptors (cetirizine) to reduce allergic inflammation and symptoms.
This combination blocks leukotriene receptors (montelukast) and histamine H1 receptors (cetirizine) to reduce allergic inflammation and symptoms. Used for Allergic rhinitis, Asthma (mild persistent), Allergic conditions with both leukotriene and histamine involvement.
At a glance
| Generic name | montelukast and cetirizine |
|---|---|
| Sponsor | Medical University of Lodz |
| Drug class | Leukotriene receptor antagonist and H1-receptor antagonist combination |
| Target | CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
Montelukast is a cysteinyl leukotriene receptor antagonist that inhibits inflammatory mediators involved in asthma and allergic rhinitis. Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Together, they target complementary pathways in allergic and inflammatory conditions.
Approved indications
- Allergic rhinitis
- Asthma (mild persistent)
- Allergic conditions with both leukotriene and histamine involvement
Common side effects
- Headache
- Somnolence
- Pharyngitis
- Abdominal pain
Key clinical trials
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme (PHASE4)
- The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
- Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- montelukast and cetirizine CI brief — competitive landscape report
- montelukast and cetirizine updates RSS · CI watch RSS
- Medical University of Lodz portfolio CI
Frequently asked questions about montelukast and cetirizine
What is montelukast and cetirizine?
How does montelukast and cetirizine work?
What is montelukast and cetirizine used for?
Who makes montelukast and cetirizine?
What drug class is montelukast and cetirizine in?
What development phase is montelukast and cetirizine in?
What are the side effects of montelukast and cetirizine?
What does montelukast and cetirizine target?
Related
- Drug class: All Leukotriene receptor antagonist and H1-receptor antagonist combination drugs
- Target: All drugs targeting CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)
- Manufacturer: Medical University of Lodz — full pipeline
- Therapeutic area: All drugs in Immunology / Allergy
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Asthma (mild persistent)
- Indication: Drugs for Allergic conditions with both leukotriene and histamine involvement
- Compare: montelukast and cetirizine vs similar drugs
- Pricing: montelukast and cetirizine cost, discount & access